よむ、つかう、まなぶ。
会議資料 (176 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00046.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第68回 5／25）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；III➀-73
Rituximab 375 mg/m2 on D-2 (= D6 COP) and on D1, before starting
chemotherapy.
Premedicate with paracetamol and chlorpheniramine as per BNFC dosing
and administer as per local practice.
9.4. Group C3 - CONSOLIDATION: R-IT-CYVE course n°3 and
course n°4
First R-IT-CYVE +MTX (course n°3) should start after R-COPADM2
when peripheral counts have recovered with ANC ~ 1.0 × 109/l and platelets
~ 100 × 109/l (usually by D18, but not less than D16).
Rituximab 375 mg/m2 on D1, before chemotherapy.
Premedicate with paracetamol and chlorpheniramine as per BNFC dosing
and administer as per local practice.
9.5. Group C3 – CONSOLIDATION: R-IT-CYVE 1 High dose
methotrexate
High dose methotrexate and triple IT drugs are given only following the
first R-CYVE.
Rituximab on D1
9.6. C3: R-IT-CYVE 2 (course n°4)
The 2nd R-IT-CVYE (course n°4) is without HD MTX and triple IT on
D18-19. It should start as soon as peripheral counts have recovered (ANC ~
1.0 × 109/l and platelets ~ 100 × 109/l).
Rituximab on D1
② EICNHL 及び国際 BFM 研究グループによる、小児及び思春期の
NHL に関する欧州標準臨床診療レコメンデーション
リスク B II、C1 及び C3 例における寛解導入療法として以下の記載
がある。
B-II: COP - R-COPADM - R-COPADM - R-CYM - R-CYM
C1: COP - R-COPADM - R-COPADM2 - R-CYVE - R-CYVE - m1 - m2
C3: COP - R-COPADM - R-COPADM2 - R-IT-CYVE-MTX R-IT-CYVE - m1 - m2
When to start each cycle:
After the first cycle, or pre-phase (COP) and first cycle, each course starts as
soon as an adequate clinical condition without infection, granulocytes > 1 ×
40
176/370
Rituximab 375 mg/m2 on D-2 (= D6 COP) and on D1, before starting
chemotherapy.
Premedicate with paracetamol and chlorpheniramine as per BNFC dosing
and administer as per local practice.
9.4. Group C3 - CONSOLIDATION: R-IT-CYVE course n°3 and
course n°4
First R-IT-CYVE +MTX (course n°3) should start after R-COPADM2
when peripheral counts have recovered with ANC ~ 1.0 × 109/l and platelets
~ 100 × 109/l (usually by D18, but not less than D16).
Rituximab 375 mg/m2 on D1, before chemotherapy.
Premedicate with paracetamol and chlorpheniramine as per BNFC dosing
and administer as per local practice.
9.5. Group C3 – CONSOLIDATION: R-IT-CYVE 1 High dose
methotrexate
High dose methotrexate and triple IT drugs are given only following the
first R-CYVE.
Rituximab on D1
9.6. C3: R-IT-CYVE 2 (course n°4)
The 2nd R-IT-CVYE (course n°4) is without HD MTX and triple IT on
D18-19. It should start as soon as peripheral counts have recovered (ANC ~
1.0 × 109/l and platelets ~ 100 × 109/l).
Rituximab on D1
② EICNHL 及び国際 BFM 研究グループによる、小児及び思春期の
NHL に関する欧州標準臨床診療レコメンデーション
リスク B II、C1 及び C3 例における寛解導入療法として以下の記載
がある。
B-II: COP - R-COPADM - R-COPADM - R-CYM - R-CYM
C1: COP - R-COPADM - R-COPADM2 - R-CYVE - R-CYVE - m1 - m2
C3: COP - R-COPADM - R-COPADM2 - R-IT-CYVE-MTX R-IT-CYVE - m1 - m2
When to start each cycle:
After the first cycle, or pre-phase (COP) and first cycle, each course starts as
soon as an adequate clinical condition without infection, granulocytes > 1 ×
40
176/370